Results 51 to 60 of about 34,807 (281)

Precision medicine in paediatrics: Progress and priorities

British Journal of Clinical Pharmacology, EarlyView.
Precision medicine is revolutionizing personalized healthcare, advancing both diagnostics and therapeutics at an unprecedented pace. Reviewing the paediatric applications of pharmacometrics, pharmacogenomics and advanced therapy medicinal products highlights not only the relevance of these exciting innovations to frontline care but also the significant
Nicola Husain, Claire Booth, Joseph F. Standing, Charlotte I. S. Barker   +3 more
wiley   +1 more source

An immunostimulatory dual-functional nanocarrier that improves cancer immunochemotherapy

Nature Communications, 2016
The use of immunostimulatory agents to enhance the efficacy of chemotherapy is a promising strategy in cancer therapy. Here, the authors report on a micellar nanoparticle that can effectively co-deliver chemo- and immunotherapeutics, resulting in an ...
Yichao Chen, Rui Xia, Yixian Huang, Wenchen Zhao, Jiang Li, Xiaolan Zhang, Pengcheng Wang, Raman Venkataramanan, Jie Fan, Wen Xie, Xiaochao Ma, Binfeng Lu, Song Li   +12 more
doaj   +1 more source

Pharmacogenetics of Antipsychotics [PDF]

The Canadian Journal of Psychiatry, 2014
Objective: During the past decades, increasing efforts have been invested in studies to unravel the influence of genetic factors on antipsychotic (AP) dosage, treatment response, and occurrence of adverse effects.
Eva J, Brandl, James L, Kennedy, Daniel J, Müller   +2 more
openaire   +2 more sources

Cost‐effectiveness of DPYD genotyping prior to fluoropyrimidine‐based treatment for colorectal cancer in Wales

British Journal of Clinical Pharmacology, EarlyView.
Abstract Background Regulatory guidance in the United Kingdom advises DPYD genotyping prior to fluoropyrimidine‐based treatment. This economic evaluation estimated the costs and outcomes associated with DPYD screening prior to prescribing fluoropyrimidines for colorectal cancer in Wales and also considers additional variants to those included in ...
Catrin O. Plumpton, Sian M. Morgan, Richard A. Adams, Samantha Cox, Angharad A. Rudkin, Megan Fealey, Craig Barrington, Michelle D. Wood, Dyfrig A. Hughes   +8 more
wiley   +1 more source

HLA‐B*15:21 carrier status is a susceptibility factor of carbamazepine‐induced nonimmediate cutaneous adverse reactions in HLA‐B*15:02‐negative patients: A retrospective cohort study

British Journal of Clinical Pharmacology, EarlyView.
After HLA‐B*15:02 screening, the residual risk of carbamazepine‐induced nonimmediate cutaneous adverse reactions is 0.059. Among these HLA‐B*15:02‐negative cases, HLA‐B*15:11 and HLA‐B*15:21 carrier status significantly increases the risk of carbamazepine‐induced nonimmediate cADR.
Warit Ruanglertboon, Chutima Seree‐aphinan, Antida Sangiemchoey, Khwanchanok Kaewpiboon, Taweesak Maneerot, Oradawan Plong‐on, Pornsiri Sangmanee, Punthipa Nichanon, Jariya Khayman, Jiraphan Manee, Areerat Hnoonual, Kanoot Jaruthamsophon   +11 more
wiley   +1 more source

CRISPR activation screens identify oncogenic lncRNAs that are susceptible to CDK4/6 inhibitor treatment

Nature Communications
The roles of long non-coding RNAs (lncRNAs) in tumorigenesis and therapeutic response remain largely unknown. Here we perform genome-wide and focused CRISPR activation screens to identify lncRNAs regulating palbociclib response in breast cancer cells.
Yifei Wang, Yueshan Zhao, Jiaxin Hu, Zehua Wang, Dhamotharan Pattarayan, Sihan Li, Yu Zhang, Xiaofei Wang, Yue Wang, Wen Xie, Min Zhang, Da Yang   +11 more
doaj   +1 more source

Exposure to CYP2C19‐metabolized drugs following acute stroke: A longitudinal cohort study to inform implementation of CYP2C19 genotype testing

British Journal of Clinical Pharmacology, EarlyView.
Aims Cytochrome P450 2C19 (CYP2C19) genotype testing is recommended to guide antiplatelet selection after ischaemic stroke and transient ischaemic attack. CYP2C19 also metabolizes several commonly prescribed non‐antiplatelet drugs. We aimed to quantify exposure to CYP2C19‐metabolized drugs in stroke patients at hospital discharge and during ...
Cleodie C. Swire, Andrew T. Lambarth, Ayesha Saleem, Daniel R. Burrage   +3 more
wiley   +1 more source

An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers

, 2023
Pharmacogenetics can improve clinical outcomes by reducing adverse drug effects and enhancing therapeutic efficacy for commonly used drugs that treat a wide range of cardiovascular diseases.
Lteif, Christelle, Duarte, Julio D, Whirl-Carrillo, Michelle, Oni-Orisan, Akinyemi, Tuteja, Sony, Cavallari, Larisa H, Friede, Kevin A, Hoffecker, Glenda, Crews, Kristine R, Murphy, William A, Huang, Yimei, Aminkeng, Folefac, Voora, Deepak, Nguyen, Nam H. K, Luzum, Jasmine A, Smith, D. Max, Tantisira, Kelan, Castrichini, Matteo   +17 more
core   +1 more source

Systematic investigation of chemo-immunotherapy synergism to shift anti-PD-1 resistance in cancer

Nature Communications
Chemo-immunotherapy combinations have been regarded as one of the most practical ways to improve immunotherapy response in cancer patients. In this study, we integrate the transcriptomics data from anti-PD-1-treated tumors and compound-treated cancer ...
Yue Wang, Dhamotharan Pattarayan, Haozhe Huang, Yueshan Zhao, Sihan Li, Yifei Wang, Min Zhang, Song Li, Da Yang   +8 more
doaj   +1 more source

Chronic Activation of LXRα Sensitizes Mice to Hepatocellular Carcinoma

Hepatology Communications, 2022
The oxysterol receptor liver X receptor (LXR) is a nuclear receptor best known for its function in the regulation of lipid and cholesterol metabolism.
Yang Xie, Runzi Sun, Li Gao, Jibin Guan, Jingyuan Wang, Aaron Bell, Junjie Zhu, Min Zhang, Meishu Xu, Peipei Lu, Xinran Cai, Songrong Ren, Pengfei Xu, Satdarshan P. Monga, Xiaochao Ma, Da Yang, Yulan Liu, Binfeng Lu, Wen Xie   +18 more
doaj   +1 more source